Hemostatic complications of cardiopulmonary bypass
- 1 April 1995
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 48 (4), 267-272
- https://doi.org/10.1002/ajh.2830480412
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusionThe Journal of Thoracic and Cardiovascular Surgery, 1993
- Preoperative Aspirin Therapy and Reoperation for Bleeding After Coronary Artery Bypass SurgeryArchives of Internal Medicine, 1991
- A Trial of Desmopressin (1-Desamino-8-D-Arginine Vasopressin) to Reduce Blood Loss in Uncomplicated Cardiac SurgeryNew England Journal of Medicine, 1989
- Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin- alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypassBlood, 1989
- Treatment with Desmopressin Acetate to Reduce Blood Loss after Cardiac SurgeryNew England Journal of Medicine, 1986
- Effects of Protamine Administration after Cardiopulmonary Bypass on Complement, Blood Elements, and the Hemodynamic StateThe Annals of Thoracic Surgery, 1986
- Enhanced fibrinolytic activity during cardiopulmonary bypass in open‐heart surgery in man is caused by extrinsic (tissue‐type) plasminogen activatorEuropean Journal of Clinical Investigation, 1984
- Elevated plasma fibrinopeptide A and thromboxane B2 levels during cardiopulmonary bypass.Circulation, 1980
- Effects of prostacyclin and albumin on platelet loss during in vitro simulation of extracorporeal circulationBlood, 1979
- Preservation of human platelets with prostaglandin E1 during in vitro simulation of cardiopulmonary bypass.Circulation Research, 1979